| Original language | English (US) |
|---|---|
| Pages (from-to) | 632-633 |
| Number of pages | 2 |
| Journal | Clinical Infectious Diseases |
| Volume | 35 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2002 |
Bibliographical note
Funding Information:Doxycycline may be an inexpensive fluoroquinolone-sparing alternative for treatment of CAP [5]. Thus, it deserves more attention in a state-of-the-art review of drug-resistant S. pneumoniae and the contemporary management of CAP than it received in this supplement. The absence of an interested corporate sponsor probably has contributed substantially to the unfortunate paucity of available data from clinical trials and in vitro susceptibility studies and the lack of authoritative attention to doxycycline in the treatment of CAP. If so, support from the IDSA, the Centers for Disease Control and Prevention, the Department of Veterans Affairs, the National Institutes of Health, and/or other noncommercial parties with an interest in controlling medical costs and preventing antibiotic resistance may be needed to address this deficit.
